New compositions are provided containing artemisinin dimers with high activity as anti-protozoal agents, including anti-malarial and anti-leishmanial properties, and methods for the treatment of protozoal infections, including malaria or leishmaniasis.

The present disclosure relates to concise processes for making (−)-picrotoxinin (1, PXN) and 5-methyl-picrotoxinin (20, 5MePXN), and to 5MePXN, its pharmaceutical compositions, and its method of use for inhibiting GABA.sub.A receptor.

The present disclosure relates to concise processes for making (−)-picrotoxinin (1, PXN) and 5-methyl-picrotoxinin (20, 5MePXN), and to 5MePXN, its pharmaceutical compositions, and its method of use for inhibiting GABA.sub.A receptor.

The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof. ##STR00001##

The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof. ##STR00001##

An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity. ##STR00001##

An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity. ##STR00001##

Polymers of intrinsic microporosity are provided herein. Disclosed polymers of intrinsic microporosity include modified polymers of intrinsic microporosity that include negatively charged sites or crosslinking between monomer units. Systems making use of polymers of intrinsic microporosity and modified polymers of intrinsic microporosity are also described, such as electrochemical cells and ion separation systems. Methods for making and using polymers of intrinsic microporosity and modified polymers of intrinsic microporosity are also disclosed.

Polymers of intrinsic microporosity are provided herein. Disclosed polymers of intrinsic microporosity include modified polymers of intrinsic microporosity that include negatively charged sites or crosslinking between monomer units. Systems making use of polymers of intrinsic microporosity and modified polymers of intrinsic microporosity are also described, such as electrochemical cells and ion separation systems. Methods for making and using polymers of intrinsic microporosity and modified polymers of intrinsic microporosity are also disclosed.

Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease.